SAB Biotherapeutics annual operating expenses
2020
2021
2022
2023
2024
2025
SAB Biotherapeutics Operating Expenses Growth & History (SABS)
SAB Biotherapeutics's operating expenses was $49.0M for fiscal 2025.
View full SAB Biotherapeutics company overviewSAB Biotherapeutics annual operating expenses history
| Fiscal year | Period ended | Operating expenses | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $49.0M | $4.7M | +10.67% |
| 2024 | 2024-12-31 | $44.2M | $3.9M | +9.72% |
| 2023 | 2023-12-31 | $40.3M | −$12.5M | −23.68% |
| 2022 | 2022-12-31 | $52.8M | −$21.4M | −28.88% |
| 2021 | 2021-12-31 | $74.3M | $39.6M | +114.15% |
| 2020 | 2020-12-31 | $34.7M | — | — |
SAB Biotherapeutics quarterly operating expenses
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Operating expenses | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $23.4M | $13.6M | +140.21% |
| Q1 2026 | 2026-03-31 | $20.0M | $9.2M | +85.64% |
| Q4 2025 | 2025-12-31 | $15.8M | $5.6M | +55.78% |
| Q3 2025 | 2025-09-30 | $12.7M | $1.4M | +12.11% |
| Q2 2025 | 2025-06-30 | $9.7M | −$732,835 | −7.00% |
| Q1 2025 | 2025-03-31 | $10.8M | −$1.6M | −12.67% |
| Q4 2024 | 2024-12-31 | $10.1M | −$9.1M | −47.21% |
| Q3 2024 | 2024-09-30 | $11.3M | $4.7M | +71.61% |
| Q2 2024 | 2024-06-30 | $10.5M | $3.9M | +59.47% |
| Q1 2024 | 2024-03-31 | $12.3M | $4.4M | +54.52% |
| Q4 2023 | 2023-12-31 | $19.2M | $9.2M | +91.39% |
| Q3 2023 | 2023-09-30 | $6.6M | −$4.8M | −42.18% |
| Q2 2023 | 2023-06-30 | $6.6M | −$6.3M | −49.10% |
| Q1 2023 | 2023-03-31 | $8.0M | −$10.5M | −56.87% |
| Q4 2022 | 2022-12-31 | $10.0M | −$8.4M | −45.55% |
| Q3 2022 | 2022-09-30 | $11.4M | −$7.3M | −38.96% |
| Q2 2022 | 2022-06-30 | $12.9M | −$8.2M | −38.84% |
| Q1 2022 | 2022-03-31 | $18.5M | $2.4M | +14.87% |
| Q4 2021 | 2021-12-31 | $18.4M | — | — |
| Q3 2021 | 2021-09-30 | $18.7M | — | — |
| Q2 2021 | 2021-06-30 | $21.1M | — | — |
| Q1 2021 | 2021-03-31 | $16.1M | — | — |
SAB Biotherapeutics operating expenses trends
Over the last five fiscal years, SAB Biotherapeutics's operating expenses increased from $34.7M to $49.0M, a change of $14.3M. The latest reported quarter, Q2 2026, shows $23.4M.
About the metric
What operating expenses mean
Operating expenses are the recurring costs of running a company’s business beyond the direct costs used to calculate gross profit. They commonly include selling, general and administrative expenses, research and development, and other operating costs.
Calculation and source
SEC-reported and calculated operating expenses
TickerStat uses operating expenses reported in company SEC filings when available. When a separate total is unavailable, it calculates operating expenses as aligned gross profit minus operating income for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review SAB Biotherapeutics source filings ↗